Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 14/20 | 0.64 |
| ▸ | EGFR | P00533 | 10/20 | 0.53 |
| ▸ | ABL1 | P00519 | 11/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.49 |
| ▸ | PRKDC | P78527 | 10/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.48 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 10/20 | 0.48 |
| ▸ | HCK | P08631 | 9/20 | 0.48 |
| ▸ | MTOR | P42345 | 9/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 9/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 7/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1318686 | 0.89 | SRC (0.66) | SRCEGFRABL1PIK3CDPIK3CA | |
| SCHEMBL12120715 | 0.87 | SRC (0.65) | SRCEGFRKDRRET | |
| SCHEMBL863586 | 0.87 | SRC (0.64) | SRCEGFRABL1IGF1RPIK3CD | |
| SCHEMBL863906 | 0.87 | SRC (0.64) | SRCEGFRABL1IGF1RPIK3CD | |
| SCHEMBL14617694 | 0.87 | SRC (0.55) | SRCEGFRABL1IGF1RPIK3CD | |
| SCHEMBL864623 | 0.87 | SRC (0.61) | SRCEGFRABL1PIK3CDPIK3CA | |
| SCHEMBL12120474 | 0.85 | SRC (0.62) | SRCEGFRRET | |
| SCHEMBL20500101 | 0.85 | SRC (0.62) | SRCEGFRABL1IGF1RPIK3CD | |
| SCHEMBL17090595 | 0.84 | LCK (0.63) | SRCEGFRABL1IGF1RPIK3CD | |
| SCHEMBL13019812 | 0.83 | PIK3CD (0.66) | SRCEGFRABL1IGF1RPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077827-A1 | ZAP-70 ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2012-03-29 | — | — | US | claimed |
| US-9862722-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2018-01-09 | — | — | US | disclosed |
| US-20150329550-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2015-11-19 | — | — | US | disclosed |
| US-9138436-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-09-22 | — | — | US | disclosed |
| US-8642606-B2 | ZAP-70 active compounds | PLEXXIKON INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120077827-A1 | ZAP-70 ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329550-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | SRC 11/4885EGFR 947/4885ABL1 1/4885 |
| US-20120077827-A1 | ZAP-70 ACTIVE COMPOUNDS | ZAP70, PRKCZ, PRKDC | SRC 25/4885EGFR 1318/4885ABL1 18/4885 |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | SRC 11/4885EGFR 947/4885ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.